The association of an individual's genetic makeup with their response to drugs is referred to
as pharmacogenomics. By understanding the relationship between genetic variants and …

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are low-
density lipoprotein cholesterol (LDL-C)-lowering drugs that play a critical role in lipoprotein …

Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player of lipid
metabolism with higher plasma levels in women throughout their life. Statin treatment affects …

This narrative review discusses an important issue, the primary role of diet in reducing low-
density lipoprotein cholesterol (LDLc) concentrations in polygenic hypercholesterolemia …

Purpose Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in
women, yet it remains underdiagnosed, undertreated, and understudied in women …

Background and aims FH women are less likely to receive intensive statin treatment and to
obtain a 50% reduction of LDL-C from baseline compared to men with FH. SLCO1B1 …

Proprotein convertase subtilisin/kexin type 9- inhibition across different patient populations
Page 1 MOL 350403 CURRENT OPINION Proprotein convertase subtilisin/kexin type 9inhibition …

Lipid-lowering therapy (LLT) is a cornerstone of atherosclerotic cardiovascular disease
prevention. Although LLT might lead to different reductions in low-density lipoprotein …

Background Lipid management in clinic is critical to the prevention and treatment of CKD,
while the manifestations of fat metabolism vary in type and have flexible correlations with …